Viemed Announces Publication of Peer-Reviewed NIVH Study


LAFAYETTE, La., July 05 Feb. 2022 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD and TSX: VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services , announced a third peer-reviewed and published study demonstrating the benefits of non-invasive home ventilation (“NIVH”). The study, titled “Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study” was published in respiratory medicinean internationally renowned scientific journal dedicated to respiratory medical research.

“In addition to the significant clinical benefits demonstrated in previously published articles, this study demonstrates that NIVH improves health outcomes while simultaneously reducing overall healthcare costs,” said Dr. William Frazier, Chief Medical Officer of Viemed and co-author of the study. “The study was also designed to investigate how the timing of NIVH initiation affected outcomes. The results showed that the clinical and financial benefits of NIVH are greater when treatment begins immediately after diagnosis. »

Using research-identifiable 100% health insurance claims from 2016 to 2020, researchers found that the use of NIVH to treat chronic obstructive pulmonary disease with chronic hypercapnic respiratory failure (COPD-CRF) is associated with significant reductions in mortality, hospitalizations, and total Medicare costs. In terms of cost savings, Medicare expenditures for the year after NIVH initiation decreased by $5,484 (11.6%) compared to controls if treatment was started within seven days of diagnosis . The cost reduction was $3412 (7.2%) if NIVH was started within 15 days of diagnosis. For patients who started treatment more than 15 days after diagnosis, the use of NIVH was cost-neutral and was not associated with increased Medicare spending.

The main clinical benefit was a reduction in mortality in patients treated with NIVH. When a patient started treatment within seven days of diagnosis, the risk of death was reduced by 43%. Patients who started treatment between eight and 15 days after diagnosis showed a mortality reduction of 31%, and patients who started treatment between 16 and 30 days after diagnosis showed a reduction in mortality of 16%.

“NIVH is increasingly accepted by clinicians as the standard of care for hypercapnic treatment of COPD-CRF and this evidence in support of early initiation will help us communicate the clinical and economic benefits to payers and partners,” said Casey Hoyt, CEO of Viemed. “By accessing and treating more patients sooner, we can save lives, reduce hospital readmissions and save money at the same time.”

The full text of the study is available online at and in the next print edition of respiratory medicine.


Viemed is a provider of home medical equipment and post-acute respiratory care services in the United States. Viemed’s service offerings focus on effective home treatment with clinical practitioners providing therapy and counseling to patients at home using state-of-the-art technology. Visit our website at

For more information, please contact:

Glen Akselrod
Bristol Capital
[email protected]

Todd Zehnder
Viemed Healthcare, Inc.
[email protected]

Forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 or “forward-looking information” as that term is defined under applicable Canadian securities laws ( collectively, “- forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “anticipates”, “expects”, “is planned”, “budget”, “potential”, “planned”, “estimates”. ‘, ‘forecasts’, ‘intends’, ‘anticipates’, ‘believes’ or ‘projects’, or negative forms thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “could”, “could”, “would”, “could” or “will be taken”, “will occur” or “will be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical facts, including those that express or imply discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance, including anticipated clinical and financial benefits of NIVH for Hypercapnic COPD-CKD Patients, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed. in forward-looking statements. These statements reflect the Company’s current beliefs and intentions with respect to future events, as well as current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by these forward-looking statements to differ from those described herein if one or more of these risks or uncertainties materializes. These factors include, but are not limited to: general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and actions taken by governmental authorities, individuals and businesses in response to the pandemic on our business, financial condition and results of operations, including on a patient base , Company revenues, employees, equipment and supplies; significant capital requirements and operational risks to which the Company may be subject; the Company’s ability to implement business strategies and seize business opportunities; the volatility of the market price of the Company’s common stock; the Company’s new business model; the risk that clinical application of treatments that show positive results in a study may not be replicated positively or that such test results may not be predictive of actual treatment outcomes or lead to adoption of such treatments by service providers ; the state of capital markets; the availability of funds and resources to continue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private paying entities; reliance on a few payers; possible discoveries of new drugs; reliance on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; permitting and licensing in a highly regulated business; competition; low profit market segments; disruptions or attacks (including cyberattacks) on the Company’s information technology, Internet, network access, or other voice or data communication systems or services; developments in various types of fraud or other criminal behavior to which the Company is exposed; non-compliance by third parties with their obligations; difficulty integrating newly acquired businesses; the impact of new laws and regulations, changes or enforcement thereof; the generally difficult legal and regulatory environment; increased competition; changes in exchange rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of catastrophic natural and unnatural events or epidemics or health issues, such as the COVID-19 pandemic, and claims resulting from such events or issues; as well as the risk factors discussed or referred to in the Company’s filings with the United States Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www., including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with securities regulatory authorities in certain provinces of Canada available at If any factor affects the Company in an unexpected way, or if the assumptions underlying the forward-looking statements prove incorrect, the actual results or events could differ materially from the results or events predicted. These forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further, the Company assumes no responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by applicable law.


Comments are closed.